News for 'SARS'

SARS may hit Infosys' China plan

SARS may hit Infosys' China plan

Rediff.com16 May 2003

Infosys Technologies Ltd said that its plan to enter China may have hit a roadblock due to the current outbreak of Severe Acute Respiratory Syndrome.

How bats carry coronavirus without getting sick

How bats carry coronavirus without getting sick

Rediff.com7 May 2020

Instead of killing bat cells as the virus does with human cells, the MERS coronavirus enters a long-term relationship with the host, maintained by the bat's unique 'super' immune system

Mumbai driver tests positive for SARS

Mumbai driver tests positive for SARS

Rediff.com28 Apr 2003

The driver, whose name has not be disclosed owing to social stigma, had been admitted to Kasturba hospital a couple of days ago and is under treatment.

Handicraft exports hit by SARS scare

Handicraft exports hit by SARS scare

Rediff.com28 Apr 2003

Suspected case of SARS in Jaipur

Suspected case of SARS in Jaipur

Rediff.com22 Apr 2003

He returned from New York and complained of high fever, fatigue and body ache.

DCGI approves commercial launch of low-cost Covid test 'Feluda'

DCGI approves commercial launch of low-cost Covid test 'Feluda'

Rediff.com20 Sep 2020

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.

Chandigarh, TN sound alert for SARS

Chandigarh, TN sound alert for SARS

Rediff.com2 Apr 2003

The alert has been sounded following reports that the killer pneumonia virus has claimed several lives and infected many others in the countries neighbouring India.

With Omicron, 3rd wave projected to hit India by Feb

With Omicron, 3rd wave projected to hit India by Feb

Rediff.com6 Dec 2021

With Omicron, the new variant of SARS-CoV2, the third wave of coronavirus could hit the peak by February with cases likely to be reaching up to 1-1.5 lakh a day in the country, but it will be milder than the second wave, Manindra Agarwal, IIT scientist involved in the mathematical projection of trajectory of COVID-19, said.

Covaxin safe, shows 77.8% efficacy against symptomatic Covid: Lancet

Covaxin safe, shows 77.8% efficacy against symptomatic Covid: Lancet

Rediff.com12 Nov 2021

The phase 3 trial findings indicate that Covaxin induces a robust antibody response with no severe vaccine-related adverse events or deaths reported among the trial participants, the authors of the study said.

Covishield produced more antibodies than Covaxin: Study

Covishield produced more antibodies than Covaxin: Study

Rediff.com7 Jun 2021

The study by a group of doctors showed that after two shots of the vaccines, 98 per cent recipients of Covishield showed antibody response, while the same was 80 per cent among Covaxin recipients. Sohini Das and Ruchika Chitravanshi report.

Delta variant counted for 60% of Delhi cases in April: Study

Delta variant counted for 60% of Delhi cases in April: Study

Rediff.com4 Jun 2021

The rapid surge in cases during Delhi's fourth COVID-19 wave was mainly driven by the Delta variant, which likely has immune-evasion properties and counted for 60 per cent of the cases in April, according to a new study.

New COVID-19 strain: Total 38 people in India test positive

New COVID-19 strain: Total 38 people in India test positive

Rediff.com4 Jan 2021

All these people have been kept in single room isolation in designated healthcare facilities by respective state governments and their close contacts have also been put under quarantine, the ministry said.

'COVID-19 is deadly in 0.1 per cent people'

'COVID-19 is deadly in 0.1 per cent people'

Rediff.com20 Oct 2020

'Some of the longer-term implications of COVID-19 are not related to the virus itself.' 'They are actually related to immune responses from the virus.'

'Omicron won't be a big challenge for India'

'Omicron won't be a big challenge for India'

Rediff.com6 Dec 2021

... 'Or any country which has reasonable vaccine coverage.' 'The emergence of Omicron clearly proves that if we allow a virus to circulate in an unvaccinated population, it would take a form which could be a Variant of Concern, or a new variant.'

2 yrs since first case reported, India has seen 7 Covid variants

2 yrs since first case reported, India has seen 7 Covid variants

Rediff.com30 Jan 2022

It was on January 30, 2020 when a third-year medical student from Wuhan university tested positive for coronavirus, becoming the country's first COVID-19 patient, days after she had returned home following semester holidays.

Oxford vaccine doing 'everything expected': Study

Oxford vaccine doing 'everything expected': Study

Rediff.com22 Oct 2020

A team at Bristol University used recently developed techniques to validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford University team.

Aerosols carrying Covid virus can travel in air up to 10m: Centre

Aerosols carrying Covid virus can travel in air up to 10m: Centre

Rediff.com21 May 2021

Nasal droplets fall within 2 metres from a COVID-19 infected person and the aerosols can travel in air up to 10 metres, the Office of the Principal Scientific Adviser said on Thursday, adding that proper ventilation can decrease the risk of transmission.

Bharat Biotech's Covaxin shipped to 11 cities in India

Bharat Biotech's Covaxin shipped to 11 cities in India

Rediff.com13 Jan 2021

After having received the government purchase order for 55 lakh doses, Bharat Biotech shipped the first batch of vaccines (each vial containing 20 doses) to Gannavaram (Vijayawada), Guwahati, Patna, Delhi, Kurukshetra, Bangalore, Pune, Bhubaneswar, Jaipur, Chennai and Lucknow.

Younger more affected by Covid as they're going out: ICMR

Younger more affected by Covid as they're going out: ICMR

Rediff.com11 May 2021

In response to a question on whether younger population were getting more affected, Indian Council of Medical Research Director General Dr Balram Bhargava said the comparison of data during the first and the second wave of COVID-19 has shown that there is not much age difference.

New Omicron sub-variant detected in countries like India: WHO

New Omicron sub-variant detected in countries like India: WHO

Rediff.com7 Jul 2022

A new sub-lineage BA.2.75 of the Omicron variant of the coronavirus has been detected in countries like India and the World Health Organisation is following this, Director-General Tedros Adhanom Ghebreyesus said.

82 cases of new strain of COVID-19 in India: Govt

82 cases of new strain of COVID-19 in India: Govt

Rediff.com8 Jan 2021

All the people who have tested positive for the new variant of the virus were kept in single-room isolation at designated healthcare facilities by the respective state governments, the ministry had earlier said.

'I told them India was like a giant jumbo jet. It would take off slowly and be unstoppable'

'I told them India was like a giant jumbo jet. It would take off slowly and be unstoppable'

Rediff.com10 Jan 2023

This doctor couple put their faith in India. And in return India has put faith in them.

51 Delta Plus cases found in 12 states, Maha tops the list: Govt

51 Delta Plus cases found in 12 states, Maha tops the list: Govt

Rediff.com25 Jun 2021

These 51 cases were detected from over 45,000 samples sequenced so far in the country.

Covishield, Covaxin work against Delta, other variants: Govt

Covishield, Covaxin work against Delta, other variants: Govt

Rediff.com25 Jun 2021

Vaccines Covishield and Covaxin work against SARS-CoV-2 variants Alpha, Beta, Gamma and Delta, while effectiveness tests against the Delta Plus variant is ongoing, the government said.

Three PSG players test positive for COVID-19

Three PSG players test positive for COVID-19

Rediff.com2 Sep 2020

Three Paris St Germain players have tested positive for COVID-19, the Ligue 1 club said on Wednesday without revealing their identities.

INSACOG suggests booster doses for people above 40 years

INSACOG suggests booster doses for people above 40 years

Rediff.com3 Dec 2021

'Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered,' the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG) said in its weekly bulletin dated November 29.

China probed weaponising COVID in 2015: Reports

China probed weaponising COVID in 2015: Reports

Rediff.com10 May 2021

The paper also includes musing that SARS -- which hit China in 2003 -- could have been a man-made bioweapon deliberately unleashed by "terrorists".

A, B blood groups, Rh+ people more prone to Covid: Study

A, B blood groups, Rh+ people more prone to Covid: Study

Rediff.com30 Nov 2021

People having blood group of A, B and those with Rh factor positive are "more susceptible to COVID-19 infection" compared to those having O or AB group and Rh negative, according to a new study conducted by doctors at a Delhi hospital.

Omicron study: Sputnik V and Light booster effective

Omicron study: Sputnik V and Light booster effective

Rediff.com22 Dec 2021

Russia's Sputnik V vaccine and its one-shot version Sputnik Light booster demonstrates high virus-neutralising activity (VNA) against the highly-contagious Omicron variant of COVID-19, providing a strong defence against severe disease and hospitalisation, according to a study.

Scientists say Oxford Covid vaccine looks safe, induces immunity

Scientists say Oxford Covid vaccine looks safe, induces immunity

Rediff.com20 Jul 2020

The results show they induced strong antibody and T-cell immune responses for up to 56 days after they were given. T-cells are crucial for maintaining protection against the virus for years.

3.2 million Indians may have died from Covid: Study

3.2 million Indians may have died from Covid: Study

Rediff.com7 Jan 2022

About 3.2 million people could have died from Covid in India by September last year, six-seven times higher than reported officially, according to a study based on one independent and two government data sources.

Antibody treatment may reduce risk in critical Covid patients: WHO

Antibody treatment may reduce risk in critical Covid patients: WHO

Rediff.com24 Sep 2021

The COVID-19 patients at high risk of hospitalisation or those with severe disease should be given a combination of two antibody treatments, according to latest World Health Organization guidelines published in The BMJ on Friday.

India-US coalition begin clinical trials for coronavirus

India-US coalition begin clinical trials for coronavirus

Rediff.com17 Mar 2020

The trial began at the Kaiser Permanente Washington Health Research Institute in Seattle as the first participant received the investigational vaccine.

Can Wastewater Testing tell us more about COVID-19?

Can Wastewater Testing tell us more about COVID-19?

Rediff.com6 Jul 2020

'Wastewater containing excreted material can tell us how a community is doing in a particular area pertaining to any epidemic, pandemic, and other bacterial and viral diseases.'

Beijing to shut coronavirus hospital, clears all cases

Beijing to shut coronavirus hospital, clears all cases

Rediff.com28 Apr 2020

Xiaotangshan Hospital in Beijing, which was used in 2003 to quarantine SARS patients, cleared all COVID-19 cases on Tuesday and is scheduled to cease operation on Wednesday, official media reported.

Mixing COVID-19 vaccines gives good protection: Study

Mixing COVID-19 vaccines gives good protection: Study

Rediff.com29 Jun 2021

According to the study, 'mixed' schedules of these vaccines induced high concentrations of antibodies against the SARS-CoV2 spike IgG protein when doses were administered four weeks apart.

Booster shots will cost Rs 100 billion

Booster shots will cost Rs 100 billion

Rediff.com24 Dec 2021

If booster shots are given on priority, the pace of vaccination may slow further. In the worst case scenario, the country will take till mid-March to vaccinate its entire adult population partially.

UK hospital told to prep for COVID vaccine by Nov: Report

UK hospital told to prep for COVID vaccine by Nov: Report

Rediff.com26 Oct 2020

The vaccine, ChAdOx1 nCoV-19 and also known as AZD1222, is considered among the most advanced in the worldwide hunt for a viable vaccine against the novel coronavirus.

No evidence Omicron has lower severity than Delta: Study

No evidence Omicron has lower severity than Delta: Study

Rediff.com20 Dec 2021

The study estimates that the risk of reinfection with the Omicron variant is 5.4 times greater than that of the Delta variant.